Solène Tatibouet
Jewish General Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Solène Tatibouet.
Seminars in Arthritis and Rheumatism | 2014
Marie Hudson; Murray Baron; Solène Tatibouet; Daniel E. Furst; Dinesh Khanna; Laura K. Hummers; Eric Hachulla; Thomas A. Medsger; Virginia D. Steen; Firas Alkassab; Sindhu R. Johnson; Øyvind Midtvedt; Gabriella Szücs; Elena Schiopu; Patricia Carreira; Chris T. Derk; Oliver Distler; Murat Inanc; Nader Khalidi; Tafazzul H. Mahmud; Maureen D. Mayes; Kevin McKown; Susanna Proudman; Lidia Rudnicka; Stuart Seigel; Jack Stein; Gabriele Valentini; Sule Yavuz; Hector Arbillaga; Beth Hazel
OBJECTIVE To determine whether exposure to angiotensin-converting enzyme (ACE) inhibitors prior to the onset of scleroderma renal crisis (SRC) leads to worse outcomes of SRC. METHODS Prospective cohort study of incident SRC subjects. The exposure of interest was ACE inhibitors prior to the onset of SRC. The outcomes of interest were death or dialysis during the first year after the onset of SRC. RESULTS A total of 87 subjects with incident SRC were identified and 1-year follow-up data were obtained in 75 (86%) subjects. Overall, 27 (36%) subjects died within the first year and an additional 19 (25%) remained on dialysis 1 year after the onset of SRC. In adjusted analyses, exposure to ACE inhibitors prior to the onset of SRC was associated with an increased risk of death (hazard ratio 2.42, 95% CI 1.02, 5.75, p < 0.05 in the primary analysis and 2.17, 95% CI 0.88, 5.33, p = 0.09 after post-hoc adjustment for pre-existing hypertension). CONCLUSION Overall, the 1-year outcomes of SRC were poor. Prior exposure to ACE inhibitors was associated with an increased risk of death after the onset of SRC, although there was uncertainty around the magnitude of the risk and the possibility of residual confounding could not be ruled out. Further studies will be needed to confirm these findings.
Arthritis Research & Therapy | 2012
Marie Hudson; Janet E. Pope; Michael Mahler; Solène Tatibouet; Russell Steele; Murray Baron; Marvin J. Fritzler
IntroductionAutoantibodies to Ro52 recently identified as TRIM21 are among the most common autoantibodies in systemic autoimmune rheumatic diseases, but their clinical association remains poorly understood. We undertook this study to determine the clinical and serologic associations of anti-Ro52/TRIM21 antibodies in patients with systemic sclerosis (SSc).MethodsDetailed clinical data and sera from 963 patients with SSc enrolled in a multicenter cohort study were collected and entered into a central database. Antibodies to Ro52/TRIM21 and other autoantibodies were detected with an addressable laser-bead immunoassay and different enzyme-linked immunosorbent assay (ELISA) systems. Associations between anti-Ro52/TRIM21 antibodies and clinical and other serologic manifestations of SSc were investigated.ResultsAnti-Ro52/TRIM21 antibodies were present in 20% of SSc patients and overlapped with other main SSc-related antibodies, including anti-centromere (by immunofluorescence and centromere protein (CENP)-A and CENP-B ELISA), anti-topoisomerase I, anti-RNA polymerase III, and anti-Pm/Scl antibodies. Anti-Ro52/TRIM21 antibodies were strongly associated with interstitial lung disease (odds ratio (OR), 1.53; 95% confidence interval (CI), 1.11 to 2.12; P = 0.0091) and overlap syndrome (OR, 2.06; 95% CI, 1.01 to 4.19; P = 0.0059).ConclusionsAnti-Ro52/TRIM21 antibodies were the second most common autoantibodies in this SSc cohort. In SSc, anti-Ro52/TRIM21 antibodies may be a marker of interstitial lung disease and overlap syndrome.
Arthritis & Rheumatism | 2014
Julie D'Aoust; Marie Hudson; Solène Tatibouet; James Wick; Michael Mahler; Murray Baron; Marvin J. Fritzler
Anti‐PM/Scl autoantibodies are found in polymyositis, dermatomyositis, systemic sclerosis (SSc), and systemic autoimmune disease overlap syndromes. PM‐1α is a major epitope of the PM/Scl complex, and antibodies against PM‐1α can be detected using a validated enzyme‐linked immunosorbent assay (ELISA). This study was undertaken to determine the prevalence and identify the clinical correlates of anti–PM‐1α antibodies in a large cohort of patients with SSc.
Arthritis Care and Research | 2015
Hebah Alhajeri; Marie Hudson; Marvin J. Fritzler; Janet E. Pope; Solène Tatibouet; Janet Markland; David Robinson; Niall Jones; Nader Khalidi; Peter Docherty; Elzbieta Kaminska; Ariel Masetto; Evelyn Sutton; Jean-Pierre Mathieu; Sophie Ligier; Tamara Grodzicky; Sharon LeClercq; Carter Thorne; Geneviève Gyger; Douglas Smith; Paul R. Fortin; Maggie Larché; Murray Baron
The goal of this study was to determine the sensitivity of the new 2013 classification criteria for systemic sclerosis (SSc; scleroderma) in an independent cohort of SSc subjects and to assess the contribution of individual items of the criteria to the overall sensitivity.
Rheumatology | 2014
Murray Baron; Marie Hudson; Solène Tatibouet; Russell Steele; Ernest Lo; Sabrina Gravel; Geneviève Gyger; Tarek El Sayegh; Janet E. Pope; Audrey Fontaine; Ariel Masseto; Debora Matthews; Evelyn Sutton; Norman Thie; Niall Jones; Maria Copete; Dean A. Kolbinson; Janet Markland; Getulio Nogueira-Filho; David Robinson; Mervyn Gornitsky
OBJECTIVE The aim of this study was to compare oral abnormalities and oral health-related quality of life (HRQoL) of patients with SSc with the general population. METHODS SSc patients and healthy controls were enrolled in a multisite cross-sectional study. A standardized oral examination was performed. Oral HRQoL was measured with the Oral Health Impact Profile (OHIP). Multivariate regression analyses were performed to identify associations between SSc, oral abnormalities and oral HRQoL. RESULTS We assessed 163 SSc patients and 231 controls. SSc patients had more decayed teeth (SSc 0.88, controls 0.59, P = 0.0465) and periodontal disease [number of teeth with pocket depth (PD) >3 mm or clinical attachment level (CAL) ≥5.5 mm; SSc 5.23, controls 2.94, P < 0.0001]. SSc patients produced less saliva (SSc 147.52 mg/min, controls 163.19 mg/min, P = 0.0259) and their interincisal distance was smaller (SSc 37.68 mm, controls 44.30 mm, P < 0.0001). SSc patients had significantly reduced oral HRQoL compared with controls (mean OHIP score: SSc 41.58, controls 26.67, P < 0.0001). Multivariate regression analyses confirmed that SSc was a significant independent predictor of missing teeth, periodontal disease, interincisal distance, saliva production and OHIP scores. CONCLUSION Subjects with SSc have impaired oral health and oral HRQoL compared with the general population. These data can be used to develop targeted interventions to improve oral health and HRQoL in SSc.
The Journal of Rheumatology | 2012
Marie Hudson; Michael Mahler; Janet E. Pope; Daniel You; Solène Tatibouet; Russell Steele; Murray Baron; Marvin J. Fritzler
Objective. To study the clinical phenotypes of centromeric proteins (CENP)-A- and CENP-B-positive patients with systemic sclerosis (SSc) and to compare them to anticentromere antibody (ACA)-positive and negative SSc patients. Methods. Sera samples were collected from 802 patients with SSc enrolled in a multicenter cohort study. Antibodies to CENP-A and B were detected by ELISA, and ACA by indirect immunofluorescence. Associations with clinical and other serological manifestations of SSc were investigated. Results. CENP-A antibodies were detected in 276 (34%), CENP-B in 286 (36%), and ACA in 279 (35%) patients. Patients having ACA, CENP-A, and/or CENP-B resembled each other and differed from the remainder of the cohort in the following respects: older chronologically and at disease onset; more commonly women; more likely to have limited disease and lower skin scores; less likely to have finger ulcers, digital tuft resorption, or finger contractures; more likely to have pulmonary hypertension; less likely to have interstitial lung disease, scleroderma renal crisis, inflammatory arthritis, and inflammatory myositis; and having lower overall disease severity. CENP-A and/or B status was predictive of the extent of skin involvement over time. Patients with limited disease who were CENP-A-negative at baseline were more likely to progress to diffuse disease compared to CENP-A-positive patients (OR 2.55, 95% CI 1.37, 4.85, p = 0.004). Conclusion. Clinical immunology laboratories are increasingly using high-throughput ELISA tests for CENP antibodies, with or without ACA detected by indirect immunofluorescence. The phenotype of CENP-A and/or B-positive patients is generally similar to that associated with ACA.
Clinical Rheumatology | 2014
Murray Baron; Lorinda Chung; Geneviève Gyger; Laura K. Hummers; Dinesh Khanna; Maureen D. Mayes; Janet E. Pope; Ami A. Shah; Virginia D. Steen; Russell Steele; Solène Tatibouet; Ariane L. Herrick; Ulf Müller-Ladner; Marie Hudson
The objectives of this study were to develop a standard classification of digital ulcers (DUs) in systemic sclerosis (SSc) for use in observational or therapeutic studies and to assess the reliability of these definitions as well as of the measurement of ulcer area. Ten North American rheumatologists with expertise in SSc reviewed multiple photos of DUs, examined four SSc subjects with DUs, and came to a consensus on the definitions for digital, active, healed, and indeterminate ulcers. These ten raters then examined the right hand of ten SSc subjects twice and the left hand once to classify ulcers and to measure ulcer area. Weighted and Fleiss kappa were used to calculate intra- and interrater agreement on classification of ulcers, and intraclass correlation coefficient (ICC) was used to assess agreement on ulcer area. Because the traditional ICC calculations relied on a small number of ulcers, ICCs were recalculated using the results of linear mixed models to evaluate the variance components of observations on all the data. Intrarater kappa for classifying DU as not an ulcer/healed ulcer versus active/indeterminate ulcer was substantial (0.76), and interrater kappa was moderate (0.53). The ICC for ulcer area using the linear mixed models was moderate both for intrarater (0.57) and interrater (0.48) measurements. A consensus for the classification of DUs in SSc was developed, and after a training session, rheumatologists with expertise in SSc are able to reliably classify DUs and to measure ulcer area.
Arthritis & Rheumatism | 2017
Yanjie Hao; Marie Hudson; Murray Baron; Patricia Carreira; Wendy Stevens; Candice Rabusa; Solène Tatibouet; Loreto Carmona; Beatriz Joven; Molla Huq; Susanna Proudman; Mandana Nikpour
To determine mortality and causes of death in a multinational inception cohort of subjects with systemic sclerosis (SSc).
Oral Surgery, Oral Medicine, Oral Pathology, and Oral Radiology | 2015
Marie Dagenais; David MacDonald; Murray Baron; Marie Hudson; Solène Tatibouet; Russell Steele; Sabrina Gravel; Shrisha Mohit; Tarek El Sayegh; Janet E. Pope; Audrey Fontaine; Ariel Masseto; Debora Matthews; Evelyn Sutton; Norman Thie; Niall Jones; Maria Copete; Dean A. Kolbinson; Janet Markland; Getulio Nogueira-Filho; David Robinson; Mervyn Gornitsky
OBJECTIVE The aim of this study was to compare oral radiologic abnormalities associated with systemic sclerosis (SSc) against abnormalities in the general population. STUDY DESIGN Patients with SSc and healthy controls were enrolled in a multi-site cross-sectional study. Included in the radiology examination were a panoramic radiograph, four bitewings, and an anterior mandibular periapical radiograph. Radiographs were evaluated by two oral and maxillofacial radiologists tested for interobserver and intraobserver reliability. Chi-squared tests, Fisher exact tests, and Mann Whitney U tests were used to summarize the radiologic manifestations of patients and controls. RESULTS We assessed 163 SSc patients and 231 controls. Widening of the periodontal ligament space (PLS) (P < .001), with higher percentage of teeth with PLS widening (P < .001), was significantly more frequent in patients with SSc than in controls. The most significant differences between the two groups were found in the molars and premolars (P < .001). Moreover, 26% of the patients with SSc had a periapical PLS greater than 0.19 mm compared with 13% of the controls (P = .003). Patients with SSc had significantly more erosions compared with controls (14.5% vs. 3.6%; P < .001), mostly in the condyles (P = .022), coronoid processes (P = .005) and other locations (P = .012). CONCLUSION Patients with SSc had more teeth with PLS widening and erosions of the mandible compared with controls.
Arthritis Care and Research | 2015
Murray Baron; Marie Hudson; Solène Tatibouet; Russell Steele; Ernest Lo; Sabrina Gravel; Geneviève Gyger; Tarek El Sayegh; Janet E. Pope; Audrey Fontaine; Ariel Masetto; Debora Matthews; Evelyn Sutton; Norman Thie; Niall Jones; Maria Copete; Dean A. Kolbinson; Janet Markland; Getulio Nogueira; David Robinson; Marvin J. Fritzler; Mervyn Gornitsky
Systemic sclerosis (SSc; scleroderma) is associated with decreased saliva production and interincisal distance, more missing teeth, and periodontal disease. We undertook this study to determine the clinical correlates of SSc with these oral abnormalities.